# Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

> **NCT03167242** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 524 (actual)

## Conditions studied

- Acute Uncomplicated Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** KAF156
- **DRUG:** Coartem
- **DRUG:** Lumefantrine Solid Dispersion Formulation

## Key facts

- **NCT ID:** NCT03167242
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-02
- **Primary completion:** 2021-06-14
- **Final completion:** 2021-06-28
- **Target enrollment:** 524 (ACTUAL)
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167242, "Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03167242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*